ArticleCurrent pharmacogenomics and personalized medicine2011
Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells.
Article in Current pharmacogenomics and personalized medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Production of a Health Awareness Video on Precautionary Measures Against Respiratory Infectious Diseases for Public Transportation Drivers: Protocol for a Scoping Review, a Delphi Study, and a Randomized Controlled Trial.JMIR research protocols · 2026Article
- Bacterial cellulose membrane combined with BMSCs promotes wound healing by activating the notch signaling pathway.Frontiers in surgery · 2022Article
- Assessment of Short-Term Engraftment Potential of Ex Vivo Expanded Hematopoietic Stem Cells Using Normal Fetal Mouse in Utero Transplantation Model.Cell journal · 2019Article
- DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation.Stem cell research & therapy · 2019Article
- Recent advances in stem cells therapy: A focus on cancer, Parkinson's and Alzheimer's.Journal, genetic engineering & biotechnology · 2018Review
- The hematopoietic system in the context of regenerative medicine.Methods (San Diego, Calif.) · 2016Review
- Regression modeling to inform cell incorporation into therapies for craniosynostosis.The Journal of craniofacial surgery · 2013Article
- Stem cell therapy for voiding and erectile dysfunction.Nature reviews. Urology · 2012Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Bone marrow transplantation is a form of cell therapy that has been in practice for decades for the treatment of hematological disorders and solid tumors. Immunosuppressive therapy has been a mainstay for treatment, but the severity of the adverse effects has made it an undesirable choice. Mesenchymal stem cells (MSCs), which reside in the vascular regions of the bone marrow, have been shown to serve as cellular support for the hematopoietic stem cell (HSC) niche. Furthermore, the immune suppressive properties of MSCs have been explored in the treatment of inflammatory and autoimmune disorders. Thus, co-therapy with MSCs has been shown to facilitate engraftment of hematopoietic cells by suppressive graft versus host disease (GvHD). Although the mechanism by which MSCs suppress GvHD is unclear, the experimental evidence suggests that this partly occurs by modulation of immune response such as the induction of regulatory T cells. This paper discusses the role of MSCs as co-therapy for the future of stem cell transplantation, with the overarching theme of personalized medicine for cell-based health interventions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.